MKI67 and breast cancer: While the average discrepancy rate in defined clinical settings for ER, PR and HER2 is frequently under debate, it is beyond any doubt that among all four breast cancer biomarkers, Ki-67 carries the highest degree of inter- and even intra-observer variability which makes scoring particularly hard to reproduce even between experienced pathologists [14, 15].